ASH 2025 | Extended follow-up from a Phase I/II study of golcadomide ± rituximab in patients with R/R DLBCL

So this again was an extension on an early phase study that was looking at single agent golcadamide. So golcadamide initially in the study we dose optimized and dose expanded as a single agent and then this study was looking at golcadamide in combination with rituximab in patients with relapsed and refractory large cell. So these patients had a median of four to four and a half lines of prior therapy, including a third of them having double hit disease, and 60% of them having had prior T-cell engaging therapy with either CAR T-cells or bispecific monoclonal antibodies. We saw an excellent overall response rate of about 60% in the total cohort, and it was 45% among patients who had received prior CAR T-cells and prior bispecifics. The drug was well tolerated and lacked a lot of the other nagging immune toxicities that one sees with IMiDs, which are sort of the prior evolution of the CELMoDs. So predominantly lenalidomide for those in the audience that treat a fair amount of lymphoma, lenalidomide is generally a preferred IMiD in that context. But this did not have any significant diarrhea, no skin toxicity, and lacked a lot of the chronic nagging toxicities that you get with lenalidomide. We did see on-target neutropenia that did not lead to significantly or high rates of febrile neutropenia. And importantly, we saw durable and sustained responses, particularly among those patients who achieved a CR. So there were six patients who actually completed two full years of therapy and another six patients who were on ongoing treatment.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.